Diagnosis and Treatment of Metastatic Colorectal Cancer

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

(2021) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

(2020) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

(2020) Chiara Cremolini et al.   LANCET ONCOLOGY

Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway

(2020) Xinjian Xu et al.   Frontiers in Microbiology

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colon Cancer Sidedness, Presentation, and Survival at Different Stages

(2019) Mark B. Ulanja et al.   Journal of Oncology

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

(2019) Funda Meric-Bernstam et al.   LANCET ONCOLOGY

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis

(2019) Zi-Xian Wang et al.   Journal of the National Comprehensive Cancer Network

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

(2019) Cathy Eng et al.   LANCET ONCOLOGY

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

(2019) Tanios S Bekaii-Saab et al.   LANCET ONCOLOGY

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

(2018) C Cremolini et al.   ANNALS OF ONCOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

(2018) Thomas Aparicio et al.   JOURNAL OF CLINICAL ONCOLOGY

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

(2018) Rui-Hua Xu et al.   LANCET ONCOLOGY

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

(2018) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis

(2018) Alexander Baraniskin et al.   EUROPEAN JOURNAL OF CANCER

Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women

(2018) Po-Hong Liu et al.   JAMA Oncology

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

(2017) Julian Walter Holch et al.   EUROPEAN JOURNAL OF CANCER

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

(2017) Fernando Rivera et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Cancer DNA in the Circulation

(2017) Hatim Husain et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

(2017) Alan P. Venook et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer

(2017) Matthew B. Yurgelun et al.   JOURNAL OF CLINICAL ONCOLOGY

Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence

(2017) Jacqueline Kerr et al.   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer

(2016) Charles J Kahi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

(2016) K. Yamazaki et al.   ANNALS OF ONCOLOGY

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

(2016) D. P. Modest et al.   ANNALS OF ONCOLOGY

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

(2016) G. Folprecht et al.   ANNALS OF ONCOLOGY

Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer

(2016) Aung Ko Win et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

XELOXvs.FOLFOX in metastatic colorectal cancer: An updated meta-analysis

(2016) Yu Guo et al.   CANCER INVESTIGATION

Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation

(2016) Courtney C. Moreno et al.   Clinical Colorectal Cancer

Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis

(2016) Ulrich Nitsche et al.   DIGESTIVE SURGERY

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer

(2016) Timothy Price et al.   EUROPEAN JOURNAL OF CANCER

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

(2016) Andrea Sartore-Bianchi et al.   LANCET ONCOLOGY

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy

(2016) Cristiana Lo Nigro et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Patterns of metastasis in colon and rectal cancer

(2016) Matias Riihimäki et al.   Scientific Reports

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

(2015) Chiara Cremolini et al.   LANCET ONCOLOGY

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

(2015) Eric Van Cutsem et al.   Targeted Oncology

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

(2014) J. Goldstein et al.   ANNALS OF ONCOLOGY

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

(2014) J. Y. Douillard et al.   ANNALS OF ONCOLOGY

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

(2014) Ian Chau et al.   BMC CANCER

Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis

(2014) Yuanbiao Guo et al.   Clinical Colorectal Cancer

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

(2014) Timothy J Price et al.   LANCET ONCOLOGY

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

(2013) M. Peeters et al.   ANNALS OF ONCOLOGY

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

(2013) Josep Tabernero et al.   EUROPEAN JOURNAL OF CANCER

Identification of Lynch Syndrome Among Patients With Colorectal Cancer

(2012) Leticia Moreira et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

(2011) E. R. Cantwell-Dorris et al.   MOLECULAR CANCER THERAPEUTICS

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

(2010) G. Masi et al.   JNCI-Journal of the National Cancer Institute

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

(2008) Howard S. Hochster et al.   JOURNAL OF CLINICAL ONCOLOGY